İçeriğe geç
akaturk Akademik ölçüm

OpenAlex konusu

Acute Myocardial Infarction Research

Bu sayfa OpenAlex konu etiketine göre çalışmaları ve o konuda görünen akademisyenleri listeler. YÖKSİS temel alan / yan dal değildir.

OpenAlex 5.307 eser 210 yazar konusu

Çalışmalar

5.307 eser

  1. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice…

  2. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS: We conducted a randomized, double-blind, placebo-control…

  3. OpenAlex üst %1 OpenAlex 100.0%

    A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa895

  4. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology

  5. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. METHODS: We randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogr…

  6. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    The current background information and detailed discussion of the data can be found in ESC CardioMed - Section 53 Pregnancy and heart disease ... ... ... Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in selecting the best management strategies for an individual pat…

  7. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS: We randomly assig…

  8. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS: We randomly assig…

  9. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS: We randomly assig…

  10. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS: We randomly assig…

  11. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome. METHODS: In this doub…

  12. YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome. METHODS: In this doub…

Akademisyenler

210 akademisyen